Tuesday, November 17, 2015

Intraluminal PA band - Surgically placed, Balloon dilatable.

Feasibility and related outcome of intraluminal pulmonary artery banding

Stany Sandrio et al. EJCTS 2015;48:470-480.

Pericardial patch with a fenestration is placed inside MPA. Needs cardiopulmonary bypass to perform this surgery.
Two types: One patch with a fenestration, or Two patches sewn together at the fenestration and then, sutured inside MPA to create an hour-glass appearance.

Balloon dilatation of this patch is possible.
Significant number of patients needed ECMO support after the procedure.
Total patients 32 in the study.



Trusler rule: JTCVS 1984;88(5 Pt 1): 645-53.

Sunday, October 11, 2015

Evrolimus therapy for Rhabdomyoma

From Wagner R. et al. Echocardiography 2015. Online accessed September 2015. DOI:10.1111/echo.1 3015.

Newborn. Treated with Evrolimus (1 mg/m2 once daily). Resolution after 3 weeks of treatment. Trough level of Evrolimus was monitored. Lymphopenia and hypertriglyceridemia was noted when higher dose was used for the first 2 days.

Sunday, September 13, 2015

Congenital heart defects and receipt of special education services

Tiffany Riehle-Colarusso et al.
Pediatrics 2015;136:496-503.

Compared with children without birth defects, children with CHD were 50% more likely to receive special education services (Adjusted Prevalence Rate Ratio 1.5)

Special education categories:
Intellectual disability (aPRR 3.8)
Sensory impairment (aPRR 3.0)
Other health impairment (aPRR 2.8)
Significant developmental delay (aPRR 1.9)
Specific learning disability (1.4)

Saturday, August 22, 2015

Sildenafil - liquid preparation

Click on the image to enlarge
(10 mg/ml)


New therapy for high LDL - PCSK9 inhibitor

From an advertisement by AmGen in Cardiology News August 2015:
New therapy for high LDL level.
PCSK9 inhibitor
PCSK9 (Proprotein convertase subtilisin/kexin type 9) degrades LDL receptors in hepatocytes.
Injection Praluent (Alirocumab) 75 mg or 150 mg. self-administer, q2weeks, recently approved by FDA.



Hyperkalemia therapy - Patriomer

From Cardiology News Aug 2015
Patiromer - a pottasium binding polymer. Binds with K in GI tract and enables excretion in stool.
JAMA 2015:314:129-30.

New Heart Failure Medication - Sacubitril (Neprilysin inhibitor)

From Cardiology News Aug 2015:
RE: FDA approval for a combination medication (Sacubitril + Valsartan)
Sacubitril - a neprilysin inhibitor
Valsartaion - an angiotensin receptor blocker